S F Shariat

Summary

Publications

  1. doi request reprint Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy
    Shahrokh F Shariat
    Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA
    Eur Urol 63:371-8. 2013
  2. doi request reprint Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification
    Shahrokh F Shariat
    Brady Urologic Health Center, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York 10065, USA
    Eur Urol 62:224-31. 2012
  3. doi request reprint International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy
    Shahrokh F Shariat
    University of Texas Southwestern Medical Center, Dallas, Texas, USA
    BJU Int 105:1402-12. 2010
  4. doi request reprint An updated catalog of prostate cancer predictive tools
    Shahrokh F Shariat
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Cancer 113:3075-99. 2008
  5. doi request reprint The effect of age and gender on bladder cancer: a critical review of the literature
    Shahrokh F Shariat
    Division of Urology Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BJU Int 105:300-8. 2010
  6. doi request reprint Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study
    Shahrokh F Shariat
    Departments of Urology and Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Clin Cancer Res 15:7012-9. 2009
  7. doi request reprint p53 expression in patients with advanced urothelial cancer of the urinary bladder
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
    BJU Int 105:489-95. 2010
  8. doi request reprint p53 predictive value for pT1-2 N0 disease at radical cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA
    J Urol 182:907-13. 2009
  9. doi request reprint Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Urol 182:78-84; discussion 84. 2009
  10. doi request reprint Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Urol 183:1744-50. 2010

Detail Information

Publications83

  1. doi request reprint Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy
    Shahrokh F Shariat
    Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA
    Eur Urol 63:371-8. 2013
    ..Radical cystectomy (RC) with pelvic lymph node dissection (PLND) is the standard of care for high-risk non-muscle-invasive and muscle-invasive bladder cancer (BCa)...
  2. doi request reprint Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification
    Shahrokh F Shariat
    Brady Urologic Health Center, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York 10065, USA
    Eur Urol 62:224-31. 2012
    ..The clinical course of pT3 upper tract urothelial carcinoma (UTUC) is highly variable...
  3. doi request reprint International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy
    Shahrokh F Shariat
    University of Texas Southwestern Medical Center, Dallas, Texas, USA
    BJU Int 105:1402-12. 2010
    ..To externally validate the prognostic value of lymphovascular invasion (LVI) in a large international cohort of patients treated with radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB)...
  4. doi request reprint An updated catalog of prostate cancer predictive tools
    Shahrokh F Shariat
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Cancer 113:3075-99. 2008
    ..Nevertheless, many more predictive tools, comparisons between them, and improvements to existing tools are needed...
  5. doi request reprint The effect of age and gender on bladder cancer: a critical review of the literature
    Shahrokh F Shariat
    Division of Urology Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BJU Int 105:300-8. 2010
    ..We must strive to develop transdisciplinary collaborative efforts to provide tailored gender- and age-specific care for patients with UCB...
  6. doi request reprint Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study
    Shahrokh F Shariat
    Departments of Urology and Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Clin Cancer Res 15:7012-9. 2009
    ..Specimens showing at least 10% reactivity were considered altered. Predictive accuracy was quantified using the concordance index and 200-bootstrap resamples were used to reduce overfit bias...
  7. doi request reprint p53 expression in patients with advanced urothelial cancer of the urinary bladder
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
    BJU Int 105:489-95. 2010
    ..To test whether assessing p53 expression could improve the ability to predict disease recurrence and disease-specific survival in a multi-institutional cohort of patients with advanced urothelial carcinoma of the urinary bladder (UCB)...
  8. doi request reprint p53 predictive value for pT1-2 N0 disease at radical cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA
    J Urol 182:907-13. 2009
    ..We determined whether p53 expression would improve the prediction of disease progression after radical cystectomy for pT1-2N0M0 UCB...
  9. doi request reprint Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Urol 182:78-84; discussion 84. 2009
    ..We tested whether the combination of immunohistochemical markers could risk stratify cases of pT1 urothelial carcinoma of the bladder at radical cystectomy...
  10. doi request reprint Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Urol 183:1744-50. 2010
    ....
  11. ncbi request reprint Tissue-based molecular markers for renal cell carcinoma
    M Rink
    Department of Urology, University of Hamburg, Hamburg, Germany
    Minerva Urol Nefrol 63:293-308. 2011
    ..A large concerted effort is required to advance the field of RCC molecular marker through systematic discovery, verification, and validation...
  12. pmc Statistical consideration for clinical biomarker research in bladder cancer
    Shahrokh F Shariat
    Department of Surgery Division of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Urol Oncol 28:389-400. 2010
    ..To critically review and illustrate current methodological and statistical considerations for bladder cancer biomarker discovery and evaluation...
  13. doi request reprint Update on intravesical agents for non-muscle-invasive bladder cancer
    Shahrokh F Shariat
    Urology Service, Memorial Sloan Kettering Cancer Center, NY, USA
    Immunotherapy 2:381-92. 2010
    ..Combination intravesical therapy may be more successful than single-agent strategies. Intravesical therapy failures indicate the need to include radical cystectomy as an option in the management decision...
  14. ncbi request reprint Tissue-based molecular markers for bladder cancer
    C E Barbieri
    Department of Urology, Weill Cornell Medical Center, New York, NY, USA
    Minerva Urol Nefrol 62:241-58. 2010
    ..A combination of complementary and yet independent molecular markers will likely better capture the biologic potential of each individual bladder tumor resulting in improved clinical decision-making...
  15. pmc Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis
    Shahrokh F Shariat
    Department of Surgery Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 117:2892-7. 2011
    ..Nonetheless, the clinical significance of NMP22 remains unclear. The objective of this study was to use decision analysis to determine whether NMP22 improves medical decision-making...
  16. doi request reprint Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment
    Shahrokh F Shariat
    Brady Urologic Health Center, Weill Cornell Medical College, 525 East 68th St, Box 94, Starr 900, New York, NY 10065, USA
    Eur Urol 61:237-42. 2012
    ..Radical cystectomy (RC) with pelvic lymph node dissection (LND) is the standard of care for refractory non-muscle-invasive and muscle-invasive bladder cancer. Although consensus exists on the need for LND, its extent is still debated...
  17. ncbi request reprint Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis
    Shahrokh F Shariat
    Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, NY 10021, USA
    Arch Esp Urol 64:681-94. 2011
    ..To be able to be used commercially such a panel will have to answer clinically relevant questions in a simple and cost-effective way...
  18. doi request reprint Can nomograms be superior to other prediction tools?
    Shahrokh F Shariat
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 103:492-5; discussion 495-7. 2009
    ..We suggest the use of nomograms for the purpose of evidence-based, individualized decision-making...
  19. ncbi request reprint Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy
    Yair Lotan
    Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9110, USA
    J Clin Oncol 23:6533-9. 2005
    ..We hypothesized that bladder cancer patients with associated lymphovascular invasion (LVI) are at increased risk of occult metastases...
  20. doi request reprint Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients
    Amit Gupta
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Eur Urol 55:1124-33. 2009
    ..This axis is involved in cell proliferation, angiogenesis, extracellular matrix degradation, invasion, and metastases...
  21. ncbi request reprint E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder
    S F Shariat
    Scott Department of Urology, Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
    Urology 57:60-5. 2001
    ..This hypothesis should be evaluated in larger studies and prospective clinical trials...
  22. ncbi request reprint E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup
    R R Byrne
    Scott Department of Urology, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas, USA
    J Urol 165:1473-9. 2001
    ..Furthermore, E-cadherin status is an independent predictor of disease progression in patients treated with cystectomy for transitional cell carcinoma of the bladder...
  23. ncbi request reprint Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    J Urol 176:2414-22; discussion 2422. 2006
    ..We present the characteristics and outcomes of a large, contemporary, consecutive series of patients treated with radical cystectomy and pelvic lymphadenectomy for transitional cell carcinoma of the bladder...
  24. ncbi request reprint Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder
    Jose A Karam
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9110, USA
    Urology 70:482-6. 2007
    ..Our objectives were to evaluate the association of survivin expression with the presence of urothelial cell carcinoma of the bladder and clinical outcomes in patients with non-muscle-invasive urothelial cell carcinoma of the bladder...
  25. ncbi request reprint Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease
    Vitaly Margulis
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Clin Cancer Res 12:7369-73. 2006
    ..We also assessed malignant lymph nodes from 50 of the 226 cystectomy patients...
  26. doi request reprint Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma
    M Rieken
    Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA Department of Urology, University Hospital Basel, Basel, Switzerland
    Eur J Surg Oncol 40:113-20. 2014
    ..We tested the hypothesis that DM and metformin use impact oncologic outcomes of patients treated with radical nephroureterectomy (RNU) for UTUC...
  27. ncbi request reprint Screening for bladder cancer using urine-based tumor markers
    R S Svatek
    Department of Urologic Oncology, MD Anderson Cancer Center, Houston, TX, USA
    Minerva Urol Nefrol 60:247-53. 2008
    ..This article reviews the current literature regarding screening for bladder cancer using urine-based markers...
  28. ncbi request reprint Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder
    Jose A Karam
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
    Clin Cancer Res 13:4400-6. 2007
    ..Little is known about the expression of this gene in urothelial carcinoma of the bladder (UCB). We profiled DOC-2/DAB2 expression in mouse and human normal and neoplastic urothelia...
  29. doi request reprint Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 10065, USA
    J Urol 183:68-75. 2010
    ..We also assessed whether the combination of molecular markers is superior to any individual biomarker...
  30. doi request reprint Inventory of prostate cancer predictive tools
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Centre, Dallas, Texas 75390 9110, USA
    Curr Opin Urol 18:279-96. 2008
    ..We describe the patient populations to which they apply and the outcomes predicted, and record their individual characteristics...
  31. doi request reprint Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
    Daher C Chade
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 184:74-80. 2010
    ..We describe patterns of disease recurrence and progression, and identify clinical outcome predictors of primary carcinoma in situ after bacillus Calmette-Guerin therapy...
  32. doi request reprint Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer
    Vitaly Margulis
    Department of Urologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Natl Cancer Inst 101:114-9. 2009
    ....
  33. ncbi request reprint Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    J Urol 178:1229-36; discussion 1236-7. 2007
    ....
  34. ncbi request reprint Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer
    M P Herman
    Weill Cornell Medical College, New York, NY, USA
    Minerva Urol Nefrol 60:217-35. 2008
    ..At this time, urine biomarkers are utilized in a variety of clinical situations but their role is not well defined. The goal of identifying an optimal marker that will replace cystoscopy and/or cytology is still ongoing...
  35. doi request reprint Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer
    Jose A Karam
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Clin Cancer Res 14:1418-22. 2008
    ..The aim of the study was to evaluate whether preoperative plasma endoglin improves the prediction of lymph node metastases in patients with clinically localized prostate cancer...
  36. ncbi request reprint Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    Mod Pathol 20:445-59. 2007
    ..In contrast to the use of single biological markers, evaluation of their combined status may improve prognostic models and help identify patients who might benefit from adjuvant therapies and in decision-making...
  37. pmc Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder
    E Xylinas
    1 Department of Urology, Weill Cornell Medical College, New York, NY, USA 2 Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France
    Br J Cancer 109:1460-6. 2013
    ..The aim of the current study was to assess the performance of these predictive tools in a large multicentre cohort of NMIBC patients...
  38. ncbi request reprint Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis
    S F Shariat
    Baylor Prostate Center, Scott Department of Urology, Baylor College of Medicine and Methodist Hospital, Houston, Texas, USA
    Urology 58:1008-15. 2001
    ....
  39. ncbi request reprint Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer
    J L Gore
    Matsunaga-Conte Prostate Cancer Research Center, the Scott Department of Urology and Department of Pathology, Baylor College of Medicine, Houston, Texas, USA
    J Urol 165:1554-9. 2001
    ....
  40. doi request reprint Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer
    Amit Gupta
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Clin Cancer Res 14:7385-90. 2008
    ..We assessed whether preoperative plasma levels of HGF can enhance the accuracy of standard models for predicting pathologic features and clinical outcomes...
  41. doi request reprint Development of a highly accurate nomogram for prediction of the need for exploration in patients with renal trauma
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Trauma 64:1451-8. 2008
    ..To develop and validate a nomogram for predicting the need for renal exploration after renal trauma...
  42. doi request reprint Bladder cancer in the elderly
    Shahrokh F Shariat
    Division of Urology, Sidney Kimmel Center for Prostate and Urologic Cancer, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Urol Oncol 27:653-67. 2009
    ..Because of the close link between age and incidence of bladder cancer, it can be expected that this disease will become an enormous challenge with the growth of an aging population in the years ahead...
  43. ncbi request reprint Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer
    Ben Andrews
    Scott Department of Urology, Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
    J Urol 167:1475-81. 2002
    ..We tested the hypothesis that preoperative plasma IL-6 and IL-6sR levels would predict cancer stage and prognosis in patients with transitional cell carcinoma of the bladder...
  44. ncbi request reprint Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma
    Robert S Svatek
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Urol 179:478-84; discussion 484. 2008
    ..We tested the hypothesis that urinary cathepsin B and L are associated with bladder cancer recurrence and invasiveness in patients with a history of nonmuscle invasive urothelial carcinoma of the bladder...
  45. ncbi request reprint Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9110, USA
    Eur Urol 45:304-13; author reply 313. 2004
    ....
  46. doi request reprint Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence
    Robert S Svatek
    Department of Urology, University of Texas Southwestern Medical Centre, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Prostate 69:886-94. 2009
    ..We tested the ability of several pre-operative blood-based biomarkers to enhance the accuracy of standard post-operative features for the prediction of biochemical recurrence (BCR) after radical prostatectomy (RP)...
  47. ncbi request reprint Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    Eur Urol 51:152-60. 2007
    ..The aim of this study was to assess whether presence of concomitant CIS has a detrimental effect on cancer control after radical cystectomy...
  48. ncbi request reprint Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy
    Jose A Karam
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Lancet Oncol 8:128-36. 2007
    ....
  49. pmc Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling
    E Xylinas
    Department of Urology, Weill Cornell Medical College, Starr 900, 525 East 68th Street, Box 94, New York, NY 10065, USA
    Br J Cancer 107:1826-32. 2012
    ..In pT1-T3N0 urothelial carcinoma of the bladder (UCB) patients, multi-modal therapy is inconsistently recommended. The aim of the study was to develop a prognostic tool to help decision-making regarding adjuvant therapy...
  50. doi request reprint Collecting system invasion and Fuhrman grade but not tumor size facilitate prognostic stratification of patients with pT2 renal cell carcinoma
    S Brookman-May
    Department of Urology, University Regensburg, Caritas St Josef Medical Center, Regensburg, Germany
    J Urol 186:2175-81. 2011
    ..In the present multicenter study the influence of tumor size as well as further clinical and histopathological parameters on cancer specific survival in patients with pT2 tumors was evaluated...
  51. ncbi request reprint Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, TX 75390 9110, USA
    Hum Pathol 37:1568-76. 2006
    ..Cyclin E1 expression stratifies patients with bladder transitional cell carcinoma into those with more "indolent" behavior and those with features of biologically and clinically aggressive disease...
  52. ncbi request reprint Survivin expression is associated with features of biologically aggressive prostate carcinoma
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 91120, USA
    Cancer 100:751-7. 2004
    ....
  53. ncbi request reprint Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review
    Daher C Chade
    Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int Braz J Urol 35:640-50; discussion 651. 2009
    ..Future perspectives and promising advances in drug development are discussed and areas of improvement are identified in order to promote better cancer control and decrease the rate and severity of side-effects...
  54. ncbi request reprint Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml
    Shahrokh F Shariat
    Department of Urology, The University of Texas Southwestern Medical Center at Dallas, TX 75390 9110, USA
    Eur Urol 49:293-302. 2006
    ..To evaluate the association of total prostate specific antigen (T-PSA) and percent free PSA (%F-PSA) with prostate cancer outcomes in patients treated with radical prostatectomy (RP)...
  55. ncbi request reprint Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder
    Shahrokh F Shariat
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    J Urol 173:1518-25. 2005
    ..We developed and validated nomograms that accurately predict disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma (TCC) of the bladder using a large international cohort...
  56. ncbi request reprint Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    BJU Int 101:232-7. 2008
    ....
  57. ncbi request reprint Survivin expression is associated with bladder cancer presence, stage, progression, and mortality
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Texas 75390 9110, USA
    Cancer 109:1106-13. 2007
    ....
  58. ncbi request reprint Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Cancer 112:315-25. 2008
    ....
  59. doi request reprint Predicting survival after radical cystectomy for bladder cancer
    Vitaly Margulis
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX 77030, USA
    BJU Int 102:15-22. 2008
    ..Significant progress has been made in identifying important molecular markers of disease and the development of multifactorial tools for predicting the outcome after RC...
  60. ncbi request reprint Nomograms provide improved accuracy for predicting survival after radical cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, and The Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA
    Clin Cancer Res 12:6663-76. 2006
    ....
  61. ncbi request reprint Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder
    Vitaly Margulis
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9110, USA
    J Urol 177:1163-8. 2007
    ....
  62. ncbi request reprint Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis
    Shahrokh F Shariat
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    J Clin Oncol 25:349-55. 2007
    ..To assess whether preoperative plasma levels of urokinase-type plasminogen activator (uPA) and its soluble receptor (uPAR) would predict cancer of the prostate (CaP) presence, stage, and prognosis...
  63. ncbi request reprint Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    J Urol 177:481-7; discussion 487. 2007
    ..We determined whether the combined expression of p53, p21, p27 and pRB is associated with outcomes of patients with nonmuscle invasive bladder transitional cell carcinoma...
  64. ncbi request reprint New circulating biomarkers for prostate cancer
    K Bensalah
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    Prostate Cancer Prostatic Dis 11:112-20. 2008
    ....
  65. ncbi request reprint Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder
    Shahrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine and Methodist Hospital, Houston, Texas, USA
    J Urol 169:938-42. 2003
    ..We describe cyclooxygenase-2 (COX-2) expression patterns in patients with carcinoma in situ and/or stage T1 transitional cell carcinoma. We determined whether expression is associated with clinical outcome in these patients...
  66. ncbi request reprint Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder
    Shahrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine and Methodist Hospital, Houston, Texas, USA
    Urology 61:1140-5. 2003
    ..To determine whether p53 and p21 expression in bladder carcinoma in situ (CIS) with or without papillary disease can predict disease recurrence, progression, and survival...
  67. ncbi request reprint Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts
    Bahaa S Malaeb
    Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA
    Urol Oncol 25:291-7. 2007
    ..To evaluate the feasibility of radical retropubic prostatectomy (RRP) as an option for treating men older than 70 years with organ confined prostate cancer and to compare biochemical progression-free survival with younger cohorts...
  68. doi request reprint Nomograms for bladder cancer
    Shahrokh F Shariat
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    Eur Urol 54:41-53. 2008
    ..Physicians need tools to accurately estimate the risk of recurrence and cancer-specific mortality to recommend individualized therapy and to design appropriate clinical trials...
  69. doi request reprint Clinical outcome of primary versus secondary bladder carcinoma in situ
    Daher C Chade
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 184:464-9. 2010
    ..Differences in clinical outcome are still unclear between primary and secondary bladder carcinoma in situ. We compared the clinical outcomes of primary and secondary carcinoma in situ, and identified predictive factors...
  70. ncbi request reprint Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    JAMA 291:1325-32. 2004
    ..Salvage radiotherapy may potentially cure patients with disease recurrence after radical prostatectomy, but previous evidence has suggested that it is ineffective in patients at the highest risk of metastatic disease progression...
  71. ncbi request reprint Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy
    Seyed M Khoddami
    Department of Urology, The University of Texas South Western Medical Center, Dallas, USA
    BJU Int 94:42-6. 2004
    ..To examine whether Gleason score (GS) 3 + 4 and 4 + 3 cancers at radical prostatectomy behave differently and whether this behaviour is independently associated with prostate cancer outcome...
  72. doi request reprint Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer
    David S Yee
    Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 183:1751-6. 2010
    ..We compared the outcomes of patients with bladder cancer previously treated for prostate cancer with radiotherapy vs other treatment modalities...
  73. ncbi request reprint Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Eur Urol 51:137-49; discussion 149-51. 2007
    ..We compared clinical and pathologic staging in a large, contemporary, consecutive series of patients who were treated with radical cystectomy and pelvic lymphadenectomy, and determined the effect of stage discrepancy on outcomes...
  74. ncbi request reprint Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer
    Robert S Svatek
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Cancer 106:1701-7. 2006
    ....
  75. doi request reprint Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy
    M Rieken
    1 Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA 2 Department of Urology, University Hospital Basel, Basel, Switzerland
    Prostate Cancer Prostatic Dis 16:367-71. 2013
    ..The impact of statin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial...
  76. doi request reprint [Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer]
    C R E Mazzola
    Department of Clinical Laboratories, Memorial Sloan Kettering Cancer Center, 1275, York Avenue, New York City, NY 10065, Etats Unis
    Prog Urol 21:1-10. 2011
    ..In this article, we review those biomarkers and then discuss the challenges a biomarker has to undergo before it is approved in a clinical use...
  77. ncbi request reprint Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence
    Jose A Karam
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    Prostate 67:614-22. 2007
    ....
  78. ncbi request reprint Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    J Urol 171:1122-7. 2004
    ..We examined whether invasion of lymphatic and/or vascular vessels (LVI), or perineural spaces (PNI) is associated with prostate cancer features and outcome...
  79. doi request reprint Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection
    Yair Lotan
    Department of Urology, University of Texas, Southwestern Medical Center, Dallas, TX 75390, USA
    BJU Int 101:1362-7. 2008
    ..Newton, MA, USA) for the detection of bladder cancer, as this is a point-of-care assay that measures NMPs in voided urine...
  80. doi request reprint Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    J Urol 179:1593-7. 2008
    ....
  81. doi request reprint Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy
    Shahrokh F Shariat
    University of Texas Southwestern, Dallas, TX, USA
    BJU Int 105:1672-7. 2010
    ..To assess the impact of patient age on outcomes after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC)...
  82. ncbi request reprint Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, 75390 9110, USA
    Eur Urol 48:424-31. 2005
    ....
  83. doi request reprint Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder
    E Xylinas
    Department of Urology, Weill Cornell Medical College, New York, NY, USA Inserm U955 Equipe 07, Université Paris Est Créteil, Creteil, France Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France
    Eur J Surg Oncol 40:121-7. 2014
    ..Expression of T-cell co-regulatory proteins has been associated with worse outcomes in patients with UCB. We aimed to confirm these findings...